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Surgical excision versus imiquimod 5% cream for nodular 
and superﬁ cial basal-cell carcinoma (SINS): a multicentre, 
non-inferiority, randomised controlled trial
Fiona Bath-Hextall, Mara Ozolins, Sarah J Armstrong, Graham B Colver, William Perkins, Paul S J Miller, Hywel C Williams, on behalf of the Surgery 
versus Imiquimod for Nodular and Superﬁ cial basal cell carcinoma (SINS) study group*
Summary
Background Basal-cell carcinoma is the most common form of skin cancer and its incidence is increasing worldwide. 
We aimed to assess the eﬀ ectiveness of imiquimod cream versus surgical excision in patients with low-risk basal-cell 
carcinoma.
Methods We did a multicentre, parallel-group, pragmatic, non-inferiority, randomised controlled trial at 12 centres in 
the UK, in which patients were recruited between June 19, 2003, and Feb 22, 2007, with 3 year follow-up from June 26, 
2006, to May 26, 2010. Participants of any age were eligible if they had histologically conﬁ rmed primary nodular or 
superﬁ cial basal-cell carcinoma at low-risk sites. We excluded patients with morphoeic or recurrent basal-cell 
carcinoma and those with Gorlin syndrome. Participants were randomly assigned (1:1) via computer-generated 
blocked randomisation, stratiﬁ ed by centre and tumour type, to receive either imiquimod 5% cream once daily for 
6 weeks (superﬁ cial) or 12 weeks (nodular), or surgical excision with a 4 mm margin. The randomisation sequence 
was concealed from study investigators. Because of the nature of the interventions, masking of participants was not 
possible and masking of outcome assessors was only partly possible. The trial statistician was masked to allocation 
until all analyses had been done. The primary outcome was the proportion of participants with clinical success, 
deﬁ ned as absence of initial treatment failure or signs of recurrence at 3 years from start of treatment. We used a 
prespeciﬁ ed non-inferiority margin of a relative risk (RR) of 0·87. Analysis was by a modiﬁ ed intention-to-treat 
population and per protocol. This study is registered as an International Standard Randomised Controlled Trial 
(ISRCTN48755084), and with ClinicalTrials.gov, number NCT00066872.
Findings 501 participants were randomly assigned to the imiquimod group (n=254) or the surgical excision group 
(n=247). At year 3, 401 (80%) patients were included in the modiﬁ ed intention-to-treat group. At 3 years, 178 (84%) of 
213 participants in the imiquimod group were treated successfully compared with 185 (98%) of 188 participants in the 
surgery group (RR 0·84, 98% CI 0·78–0·91; p<0·0001). No clear diﬀ erence was noted between groups in patient-
assessed cosmetic outcomes. The most common adverse events were itching (211 patients in the imiquimod group vs 
129 in the surgery group) and weeping (160 vs 81). We recorded serious adverse events in 99 (40%) of 249 participants 
in the imiquimod group and 97 (42%) of 229 in the surgery group had serious adverse events, but none were regarded 
as related to treatment. 12 (5%) participants in the imiquimod group withdrew because of adverse events compared 
with four (2%) in the surgery group.
Interpretation Imiquimod was inferior to surgery according to our predeﬁ ned non-inferiority criterion. Although 
excisional surgery remains the best treatment for low-risk basal-cell carcinoma, imiquimod cream might still be a 
useful treatment option for small low-risk superﬁ cial or nodular basal-cell carcinoma dependent on factors such as 
patient preference, size and site of the lesion, and whether the patient has more than one lesion.
Funding Cancer Research UK.
Introduction
Basal-cell carcinomas make up 80% of all skin cancers 
and are the most common malignant disease in white 
populations. The incidence of basal-cell carcinoma is 
increasing worldwide by up to 10% per year,1 and is also 
increasing in young people.2–4 Skin cancer is a growing 
health problem and puts a substantial burden on the 
resources of health-care systems.5,6 Although various 
treatment options are available for patients with low-risk 
basal-cell carcinoma, surgery is regarded as the gold 
standard.7 Surgical treatment is largely done by 
dermatologists and plastic surgeons, although treatment 
of low-risk disease can be undertaken by other health-
care professionals with additional skills in skin cancer—
eg, by family doctors or by professionals at local 
community hospital or treatment centres.8
Studies identiﬁ ed in our previous systematic review7 
have reported successful treatment with imiquimod 
cream; with 87–88% of patients with superﬁ cial basal-
cell carcinoma, using a once-daily regimen for 6 weeks 
being successfully treated, and 76% of patients with 
nodular disease following once-daily treatment for 
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12 weeks.7,9 However, none of these studies compared 
imiquimod with surgery. Imiquimod is an immune-
response enhancer that probably works by activating 
toll-like receptor-7. The medicine is licensed in a cream 
form to be applied by patients for the treatment of 
external genital warts, superﬁ cial basal-cell carcinoma, 
and actinic keratoses in adults.10–12 We postulated that 
topical imiquimod, although inferior to surgery, could 
still be an acceptable alternative because it might result 
in a better cosmetic appearance, especially for patients 
with low-risk basal-cell carcinomas of the face and neck, 
and because of the convenience of home application, 
plus possible cost and service savings. In this randomised 
study, we assessed whether imiquimod cream was non-
inferior to surgical excision for treatment of low-risk 
basal-cell carcinoma.
Methods
Study design and patients  
We undertook this multicentre, parallel-group, 
pragmatic, randomised, non-inferiority trial, in which 
patients were recruited between June 19, 2003, and 
Feb 22, 2007, with 3 year follow-up in clinic from June 26, 
2006, to May 26, 2010, and longer follow-up from patients’ 
notes from the last trial visit until up to 5 years and 
4 weeks after the start of treatment. Participants were 
initially recruited from three dermatology secondary-care 
centres in the UK; from 2004 to 2006 an additional nine 
centres were added. The appendix has details of the study 
centres and participant recruitment. The study protocol 
has been previously published.13
Eligible participants of any age had histologically 
conﬁ rmed, primary, previously untreated, nodular or 
superﬁ cial basal-cell carcinoma not arising at sites at 
high risk for subclinical tumour spread, including the 
nose, ear, eyelid, eyebrow, and temple.14 We excluded 
patients with morphoeic or recurrent basal-cell 
carcinoma and those with Gorlin syndrome.
The study had full ethics approval from the Nottingham 
Research Ethics Committee 2; all other sites had ethics 
approval. All participants gave written informed consent.
Randomisation and masking  
Participants were randomly assigned (1:1) via computer-
generated blocked randomisation to receive topical 
imiquimod 5% cream or surgical excision with a 4 mm 
margin. The allocation sequence was prepared by the 
Trent Research and Development Support Unit 
(RDSU; Nottingham, UK) and randomisation was 
stratiﬁ ed by centre and type of basal-cell carcinoma. 
The research nurse was required to telephone Trent 
RDSU to obtain the allocated treatment for the next 
participant, which concealed the randomisation 
sequence from investigators. The Trent RDSU recorded 
the name of the next participant to be recruited and 
logged the date of the telephone call against the 
participant’s identiﬁ cation number before specifying 
the treatment to which the participant was randomised. 
The research nurse arranged for the allocated treatment 
to be started and completed the case report forms. All 
allocated identiﬁ cation numbers were included in the 
database.
Because of the nature of the interventions, masking of 
participants was not possible. Masking of outcome 
assessors was only partly possible because surgery left a 
visible scar. The trial statistician was masked to allocation 
until all analyses had been done.
Figure: Trial proﬁ le
*Numbers who saw the nurse were not available from some smaller centres; an unknown greater number saw a 
doctor in clinic before assessment; potential participants were directed to the nurse who explained the study. 
†Non-acceptance by eligible patients. ‡Because of unsuitable histology, death, poor health, regression of basal-cell 
carcinoma, participant was no longer available for follow-up or was unable to reach. §Excluded from safety 
analysis. ¶Not known before treatment. ||Both not serious. **Electrodesiccation and curettage.
254 assigned to imiquimod 247 assigned to surgery
5 did not begin treatment
 5 had lesions that were not 
  basal-cell carcinomas
11 did not begin treatment
 7 did not accept treatment
 2 for whom treatment was 
  considered unsuitable by doctor
 1 was too ill
 1 was confused about dates
249 received allocated intervention 236 received allocated intervention
31 lost to follow-up
 10 unwilling or unable to attend
 7 died
 6 were non-contactable or had
  moved
 5 had adverse events
 2 had possibly treatment-related
  adverse events||
 1 had previously treated basal-cell
  carcinoma
41 lost to follow-up
 20 unwilling to continue§
 9 had lesions that were not
  basal-cell carcinomas¶
 7 died
 5 were non-contactable or had
  moved§
218 at 3 year follow-up 195 at 3 year follow-up
5 not analysed
 5 had a missing primary endpoint
   7 not analysed§
 2 had a missing primary endpoint
 5 had had the wrong procedure
  done by mistake§**
213 analysed 188 analysed
947 participants assessed for eligibility*
446 not randomised*
 314 excluded at screening
  44 did not meet inclusion criteria
  265 declined to participate†
  4 not suitable
  1 too frail
 132 excluded just before randomisation‡
501 randomised
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Procedures
Treatment duration and frequency of dosing for 
imiquimod 5% cream were based on results from 
previous studies.15 After the start of this study, imiquimod 
was licensed for treatment of superﬁ cial basal-cell 
carcinoma, with a 5 days per week dosing regimen. 
Patients with superﬁ cial basal-cell carcinoma were 
instructed to apply the cream once daily for a total of 
6 weeks. For patients with nodular disease, total 
application time was for 12 weeks.
Participants received an instruction sheet for how to 
apply the cream (separate sheets for nodular and 
superﬁ cial tumours). They were instructed to apply a thin 
layer to the lesion and to the 1 cm surrounding area 
before going to bed at night. The lesion was not to be 
covered (unless needed because of weeping or bleeding). 
Participants were asked to wash their hands after applying 
the cream, and to wash the cream oﬀ  from the treatment 
site in the morning. Dosing was once daily because the 
study started before the manufacturers had decided on 
the ﬁ nal dosing regimen for basal-cell carcinoma. If a 
participant could not tolerate the cream because of side-
eﬀ ects, they were advised to stop treatment for a week 
and then restart at a frequency of 5 days a week. If this 
schedule was tolerated, the participant could go back to 
7 days a week; if not, or if 7 days a week was not tolerated, 
a second time, they could go back to 5 days a week after a 
further rest period of 1 week. Treatment compliance was 
assessed for imiquimod by use of a daily diary and sachet 
returns. Patients who underwent surgery had simple 
excisional surgery with 4 mm margins (margins not 
checked). Dermatology consultants and dermatology 
trainees did surgery in line with usual local hospital 
arrangements to indicate the pragmatic nature of the 
trial. Compliance for surgery was conﬁ rmed by 
documentation of the date of surgery and whether or not 
a scar was visible at the next assessment. 
The primary outcome was the proportion of participants 
with evidence of clinical success after 3 years from start 
of treatment. Clinically successful treatment was deﬁ ned 
as no initial treatment failure or signs of subsequent 
local recurrence as reviewed by consultant dermatologists. 
We chose the 3 year timepoint for the primary endpoint 
because it was the last planned face-to-face visit that 
would enable measurement of clinical response in a way 
that would match clinical practice, and because 67% of 
recurrences of basal-cell carcinoma happen within the 
ﬁ rst 3 years after treatment.16
Secondary outcomes were clinical success at years 1, 2, 
and 5 (5 year data are not yet available); time to ﬁ rst failure 
(as stratiﬁ ed into within 1 year, between 1–2 years, and 
between 2–3 years); cosmetic appearance of lesion site as 
rated by the participant and dermatologist assessor; pain 
during treatment and in the 16 weeks of follow-up; the 
number of days the participant had moderate or severe 
pain during treatment and in the 16 week follow-up; and 
cost-eﬀ ectiveness of imiquimod versus surgery.
Statistical analysis  
The original sample size for non-inferiority was based on 
a prestudy survey of UK dermatologists (unpublished 
data), which suggested that imiquimod needed to have 
roughly a 90% minimum chance of clinical success to 
Imiquimod (n=247*) Surgery (n=220*)
Age (years) 69 (61–76) 67 (59-74)
Sex
Men 145 (59%) 133 (61%)
Women 102 (41%) 87 (40%)
Fitzpatrick skin type†
I 34 (14%) 29 (13%)
II 92 (37%) 101 (46%)
III 104 (42%) 78 (35%)
IV 15 (6%) 12 (6%)
Not recorded 2 (<1%) 0
Diameter (mm) 12 (9–16) 10 (8–15)
Site of lesion
Face 91 (37%) 72 (33%)
Neck 15 (6%) 20 (9%)
Trunk 95 (38%) 86 (39%)
Arm 16 (6%) 16 (7%)
Leg 24 (10%) 20 (9%)
Other 7 (3%) 6 (3%)
Not recorded 0 0
Immunocompromised‡
At baseline
Yes 12 (5%) 7 (3%)
No 228 (92%) 205 (94%)
Unknown 5 (2%) 1 (<1%)
Not recorded 2 (<1%) 6 (3%)
During study
Yes 3 (1%) 0
Previous basal-cell carcinoma
Yes 82 (33%) 79 (36%)
Number of previous basal-cell carcinomas
>3 19 (8%) 24 (11%)
1–3 63 (26%) 55 (25%)
0 165 (67%) 141 (64%)
Other skin cancers
Yes§ 18 (7%) 14 (6%)
No 228 (92%) 206 (94%)
Not recorded 1 (<1%) 0
Data are median (IQR) or n (%), unless otherwise indicated. *Full dataset numbers (ie, modiﬁ ed intention-to-treat 
populations). †I=pale skin, burns very easily and rarely tans; II=fair skin that usually burns, but can gradually tan; 
III=skin that burns with long or intense exposure to the sun, but generally tans quite easily; IV=olive-coloured skin 
that always tans easily, but could possibly burn with lengthy exposures to intense sunshine; V=naturally brown skin, 
with brown eyes and dark hair; skin darkens easily with sun exposure and only burns with excessive exposure to the 
sun; VI=black skin with dark brown eyes and black hair; skin very easily darkens further on exposure to sun and would 
very rarely, if ever, burn. ‡Patients who were taking immunosuppressive drugs such as oral steroids, methotrexate, 
ciclosporin for suppression of immunological disorders, or to prevent transplant rejection. §Three (1%) patients with 
other skin cancers in the imiquimod group, and seven (3%) with other cancers in the surgery group had a previous 
history of invasive melanoma.
Table 1: Baseline and demographic characteristics
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change practice, compared with a success rate of 97% for 
surgery. With a lower 98% conﬁ dence boundary of 84% 
(80% power, one-sided α=1%), giving a total sample size 
of 740. Because of recruitment diﬃ  culties, we revisited 
the sample size calculation in March, 2006. Protocol 
amendment was approved by the research ethics 
committee and the data monitoring committee. We 
explored how the lower boundary of the CI varied for a 
range of sample sizes whereas all other assumptions 
used in the original calculation of sample size remained 
the same. This calculation showed that with a total 
sample size of 500, the lower limit of the conﬁ dence 
boundary of the imiquimod response rate would be 83%, 
and the additional gain in power from increasing the 
sample size to 550 and then to 600 was small. The 
precision of the response rate estimate for imiquimod 
would be within 10 percentage points of the actual 
imiquimod success rate for a sample size of 500, which 
was deemed acceptable to change practice. The non-
inferiority margin based on these ﬁ gures is a relative risk 
of 0·87 (lower boundary of a 98% CI for the relative 
diﬀ erence in eﬀ ect expressed as a relative risk), and only 
applies to the primary outcome. The sample size and 
choice of non-inferiority margin are fully reported in the 
study protocol.13
All analyses were done according to the protocol-
speciﬁ ed statistical analysis plan, apart from the cost-
eﬀ ectiveness analysis, which we did with a diﬀ erent 
method to that originally planned because the ﬁ rst 
method was no longer appropriate. We applied t-tests, 
instead of bootstrap techniques and cost-eﬀ ectiveness 
acceptability curves, to eﬃ  cacy and cost data (appendix).
We analysed data with Stata (version 10.1).
We recorded the characteristics of participants at 
baseline and summarised them for each treatment group 
with descriptive statistics. We did a modiﬁ ed intention-
to-treat analysis on the full dataset, deﬁ ned as all 
randomised participants with a histologically conﬁ rmed 
basal-cell carcinoma lesion who met the inclusion criteria 
and received at least one application of imiquimod cream 
or surgery, and for whom the outcome being analysed 
was available. We also did a per-protocol analysis for the 
primary outcome. This analysis started with the modiﬁ ed 
intention-to-treat population, with additional exclusion 
of patients who did not comply with the protocol 
procedures: those who received insuﬃ  cient imiquimod 
(less than two-thirds of required dosing), those who had 
surgery by mistake after imiquimod, those who had 
additional surgery for early failure, and those who had 
complete curettage plus cryosurgery instead of biopsy for 
presumed treatment failure (histology negative).
We did sensitivity analyses for missing data for two 
measures: (1) the primary outcome measure (assuming 
the worst-case scenario of all participants with missing 
data having recurrence or treatment failure and the best-
case scenario of all participants with missing data having 
been successfully treated); and (2) time to failure 
(assuming the worst-case scenario with missing data 
replaced with the earliest time and the best-case scenario 
with missing data replaced with the latest time). We 
adjusted all analyses for centre, type of basal-cell 
carcinoma (superﬁ cial or nodular), size and site of 
tumour, and immunosuppression at baseline. In 
subgroup analyses for the primary outcome we assessed 
whether the intervention eﬀ ect varied by tumour type 
(superﬁ cial vs nodular), tumour site (head and neck vs 
other sites), and tumour size (≤15 mm vs >15 mm 
diameters), by incorporation of an interaction term 
between treatment group and the covariate of interest in 
the regression models.17
For the primary outcome, we calculated the number 
and proportion of participants successfully treated at 
3 years in each group, and the absolute diﬀ erence in 
percentages between groups together with corresponding 
98% CIs. We used Poisson regression with a robust error 
variance to estimate the treatment eﬀ ect as a relative 
risk.18 We analysed secondary outcome measures with 
the same method as that for the primary outcome 
variable. We rated the cosmetic outcome as excellent, 
good, fair, poor, very poor, and unable to see lesion, and 
we classed evaluable lesions as a success if they had an 
excellent or good appearance. We assessed pain daily on 
a scale consisting of no pain, and mild, mild to moderate, 
moderate, moderate to severe, and severe pain; we took 
pain during treatment to mean at least moderate pain on 
any one of the days during treatment. Time to failure 
Successfully treated 
with imiquimod
Successfully treated 
with surgery
Diﬀ erence 
(%, 98% CI)*
RR (98% CI)†‡ p value§
Modiﬁ ed intention-to-treat analysis
3 years
Superﬁ cial 97/114 (85·1%) 96/98 (98·0%) 12·9% (4·4–21·3) ·· ··
Nodular 81/99 (81·8%) 89/90 (98·9%) 17·1% (7·7–26·4) ·· ··
All 178/213 (83·6%) 185/188 (98·4%) 14·8% (8·6–21·1) 0·84 (0·78–0·91) <0·0001
2 years
Superﬁ cial 101/116 (87·1%) 99/100 (99·0%) 11·9% (4·3–19·5) ·· ··
Nodular 90/107 (84·1%) 92/93 (98·9%) 14·8% (6·2–23·4) ·· ··
All 191/223 (85·7%) 191/193 (99·0%) 13·3% (7·6–19·3) 0·86 (0·80–0·92) <0·0001
1 year
Superﬁ cial 106/119 (89·1%) 99/100 (99·0%) 9·9% (2·9–17·0) ·· ··
Nodular 95/111 (85·6%) 98/99 (99·0%) 13·4% (5·3–21·5) ·· ··
All 201/230 (87·4%) 197/199 (99·0%) 11·6% (6·3–17·0) 0·88 (0·82–0·93) <0·0001
Per-protocol analysis
3 years
Superﬁ cial 92/109 (84·4%) 96/98 (98·0%) 13·6% (4·8–22·3) ·· ··
Nodular 76/93 (81·7%) 88/89 (98·9%) 17·2% (7·5–26·8) ·· ··
All 168/202 (83·2%) 184/187 (98·4%) 15·2% (8·7–21·7) 0·83 (0·77–0·90) <0·0001
Data are n/N (%), unless otherwise indicated. RR=relative risk. *Surgery–imiquinod. †Imiquinod relative to surgery. 
‡Relative-risk analysis covariates: centre, tumour type (nodular or superﬁ cial), tumour size, tumour site, and 
immunosuppression. §From likelihood ratio test.
Table 2: Success at years 1, 2, and 3 in the modiﬁ ed intention-to-treat analysis and at year 3 in the 
per-protocol analysis
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(one of ﬁ ve between-assessment time intervals) was 
analysed with a continuation ratio model with a 
complementary log-log link to estimate hazard ratios 
(HRs), and we used descriptive statistics to summarise 
the pain outcomes. Details of the methods of analysis are 
reported in the study protocol.13 The appendix provides 
details of the cost-eﬀ ectiveness analysis.
This trial is registered as an International Standard 
Randomised Controlled Trial (ISRCTN48755084), and 
with ClinicalTrials.gov, number NCT00066872.
Role of the funding source
The sponsors of the study and the company who donated 
the imiquimod had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit it for publication.
Results
The ﬁ gure shows the trial proﬁ le. 501 participants were 
assigned to the imiquimod group (n=254) or the surgical 
excision group (n=247). 257 (51%) patients had superﬁ cial 
basal-cell carcinoma and 244 (49%) had nodular tumours 
as judged clinically on study entry. The appendix shows 
histology data. Five (2%) participants did not receive the 
intervention in the imiquimod group and 18 (7%) did 
not receive the intervention in the surgery group 
(ﬁ gure 1). Seven (39%) of these 18 participants in the 
surgery group  had a diﬀ erent surgical procedure done 
by mistake: two of these were lost to follow-up, but the 
remaining ﬁ ve were followed up to year 3 and excluded 
from the modiﬁ ed intention-to-treat analysis (ﬁ gure 1). 
Five (31%) of these 16 patients in the surgery group had 
a diﬀ erent surgical procedure done by mistake but were 
followed up to year 3 and excluded from the modiﬁ ed 
intention-to-treat analysis (ﬁ gure 1). 31 (12%) participants 
in the imiquimod group and 41 (17%) in the surgery 
group were lost to follow-up; ﬁ ve (2%) further 
participants in the imiquimod group and two (<1%) in 
the surgery group had a missing end point, leaving 
401 (80%) patients for the modiﬁ ed intention-to-treat 
analysis at year 3 (ﬁ gure 1).
Baseline characteristics were similar between the two 
groups (table 1). Median age of the participants was 
68 years (range 30–92) and more men than woman were 
enrolled (table 1). Two-thirds of participants did not 
previously have basal-cell carcinoma (table 1).
At 3 years in the modiﬁ ed intention-to-treat popu-
lation of 213 patients in the imiquimod group, and 
188 patients in the surgery group, signiﬁ cantly fewer 
participants were successfully treated in the imiquimod 
group than in the surgery group (table 2). The lower 
limit of the 98% CI for successful treatment at 3 years 
(0·78) was less than the prespeciﬁ ed non-inferiority 
margin (0·87), and the upper limit was less than 1·0 
(table 2); therefore, imiquimod was inferior to surgery. 
Similar results were shown in the per-protocol analysis 
of 202 patients in the imquimod group and 187 patients 
in the surgery group (table 2) and results were 
unchanged in sensitivity analyses for missing data (data 
not shown).
The type of basal-cell carcinoma did not aﬀ ect the 
diﬀ erence in outcome between those treated with 
imiquimod and surgery. Fewer patients with superﬁ cial 
or nodular tumours were successfully treated in the 
imiquimod group than in the surgery group (table 2). 
We noted no signiﬁ cant interactions between treatment 
eﬀ ect and tumour type, site, and size (data not shown). 
Our planned subgroup analysis showed clinical response 
rates of 92% (138/150 patients) for superﬁ cial lesions of 
15 mm or less versus 89% (55/62) for lesions of more 
than 15 mm. Corresponding values for nodular lesions 
were 90% (138/153) and 89% (32/36), respectively. These 
results are pooled (surgery and imiquimod), but the 
models ﬁ tted in the multivariate analysis adjusted for 
treatment type and centre. After 1 and 2 years of follow-
up, fewer patients, for whom the outcome data were 
available, were successfully treated in the imiquimod 
group than in the surgery group (table 2).
In the 3-year modiﬁ ed intention-to-treat population, 
signiﬁ cantly more tumours recurred or did not go away 
in patients in the imiquimod group in the ﬁ rst year of 
follow-up from start of treatment than in those in the 
surgery group (table 3). This ﬁ nding was maintained for 
years 1–2 and years 2–3 of follow-up (table 3) in the same 
patient population. Participants in the imiquimod group 
had a shorter time to failure than did those in the surgery 
group (HR 0·08, 98% CI 0·02–0·32, table 3).
Data for participant-rated cosmetic appearance (at all 
sites) did not diﬀ er signiﬁ cantly between groups at 
6 months and 3 years (appendix). Data were available for 
Imiquimod Surgery HR (98% CI); p value*
Before 1 year 1–2 years 2–3 years Number who did not fail Before 1 year 1–2 years 2–3 years Number who did not fail
Superﬁ cial 13/114 (11%) 2/114 (2%) 2/114 (2%) 97/114 (85%) 1/98 (1%) 0/98 1/98 (1%) 96/98 (98%) ··
Nodular† 16/98 (16%) 0/98 1/98 (1%) 81/98 (83%) 1/90 (1%) 0/90 0/90 89/90 (99%) ··
All 29/212 (14%) 2/212 (<1%) 3/212 (1%) 178/212 (84%) 2/188 (1%) 0/188 1/188 (<1%) 185/188 (98%) 0·08 (0·02–0·32); p<0·001
All models adjusted for centre, tumour type, tumour site, and immunosuppression *HR from continuation ratio model. †One less participant because the time category of failure was unknown for that 
participant; this individual is included in the sensitivity analyses.
Table 3: Patients who failed treatement as stratiﬁ ed by timepoints, by type of basal-cell carcinoma and treatment group (modiﬁ ed intention-to-treat analysis)
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117 patients in the imiquimod group and 109 patients in 
the surgery group, at 6 months, and in 160 imiquimod 
treated patients and 166 surgery patients at 3 years; data 
were missing because patients could not see the lesion 
sites, and at 6 months for some participants because we 
changed the scale we used. Participants rated the 
cosmetic appearance highly (as excellent or good) in 
both groups at 6 months and 3 years (appendix). Pictures 
were available for independent review for 213 patients 
treated with imquimod and 195 patients treated with 
surgery at 6 months, and 170 and 174 patients, 
respectively, at 3 years. Cosmetic appearance at all sites 
diﬀ ered signiﬁ cantly between treatment groups in 
favour of imiquimod, as rated by two independent 
dermatologists using digital images, at 6 months and 
3 years (table 4).
Data for pain during treatment were available for 
242 patients treated with imiquimod and 201 patients 
treated with surgery. 72 (30%) patients in the imiquimod 
group and 44 (22%) patients in the surgery group had 
moderate or severe pain at some time during treatment 
(treatment duration was dependent on treatment and 
type; table 5); however, 22 (9%) patients treated with 
imquimod had moderate or severe pain in the 16 weeks 
after treatment compared with 41 (20%) of patients who 
underwent surgery (table 5).
In the safety datasets, 240 (96%) of the 249 patients in 
the imiquimod group and 202 (88%) of 229 in the 
surgery group had adverse events (both related and not 
related to treatment) in the ﬁ rst 6 months after start of 
treatment (table 6). Roughly the same proportions of 
participants in both groups took drugs to manage the 
adverse events (table 6). Weeping and itching were 
common in both groups. Other less common adverse 
events included occurrence of new tumours, and 
redness and swelling at tumour site (table 7). In the 
imiquimod group, 38 (15%) participants needed a dose 
reduction. 12 (5%) participants in the imiquimod group 
During treatment Follow-up
Imiquimod Surgery Imiquimod Surgery
Superﬁ cial
No pain 44/122 (36%) 35/101 (35%) 63/122 (52%) 25/103 (24%)
Mild or mild to moderate 45/122 (37%) 44/101 (44%) 46/122 (38%) 54/103 (52%)
Moderate, moderate to severe, or severe 33/122 (27%) 22/101 (22%) 13/122 (11%) 24/103 (23%)
Nodular
No pain 29/120 (24%) 27/100 (27%) 72/111 (65%) 30/103 (29%)
Mild or mild to moderate 52/120 (43%) 51/100 (51%) 30/111 (27%) 56/103 (54%)
Moderate, moderate to severe, or severe 39/120 (33%) 22/100 (22%) 9/111 (8%) 17/103 (17%)
All
No pain 73/242 (30%) 62/201 (31%) 135/233 (58%) 55/206 (27%)
Mild or mild to moderate 97/242 (40%) 95/201 (47%) 76/233 (33%) 110/206 (53%)
Moderate, moderate to severe, or severe 72/242 (30%) 44/201 (22%) 22/233 (9%) 41/206 (20%)
Pain was recorded in daily diaries, so data were missing for some participants. 
Table 5: Pain during, and 16 weeks after, treatment
 Imiquimod Surgery Diﬀ erence (%, 98% CI)* Relative risk (98% CI)† p value‡
6 months
Superﬁ cial
Head and neck 17/30 (56·7%) 4/25 (16·0%) –40·7% (–67·8 to –13·6) ·· ··
All sites 33/112 (29·5%) 10/99 (10·1%) –19·4% (–31·6 to –7·1) ·· ··
Nodular
Head and neck 35/63 (55·6%) 18/56 (32·1%) –23·4% (–44·0 to –2·8) ·· ··
All sites 41/101 (40·6%) 22/96 (22·9%) –17·7% (–32·8 to –2·6) ·· ··
All
Head and neck§ 52/93 (55·9%) 22/81 (27·2%) –28·8% (–45·4 to –12·2) 2·00 (1·28 to 3·12) 0·0003
All sites 74/213 (34·7%) 32/195 (16·4%) –18·3% (–28·1 to 8·6) 2·15 (1·43 to 3·23) <0·0001
3 years
Superﬁ cial
Head and neck 16/26 (61·5%) 9/24 (37·5%) –24·0% (–56·0 to 7·9) ·· ··
All sites 62/93 (66·7%) 29/89 (32·6%) –34·1% (–50·3 to –17·9) ·· ··
Nodular
Head and neck 30/48 (62·5%) 20/48 (41·7%) –20·8% (–44·0 to 2·4) ·· ··
All sites 41/77 (53·3%) 33/85 (38·8%) –14·4% (–32·5 to 3·6) ·· ··
All
Head and neck 46/74 (62·2%) 29/72 (40·3%) –21·9% (–40·7 to –3·1) 1·58 (1·06–2·36) 0·007
All sites 103/170 (60·6%) 62/174 (35·6%) –25·0% (–37·1 to –12·8) 1·79 (1·36–2·36) <0·0001
Data are n/N (%), unless otherwise indicated. Analyses adjusted for centre, tumour type, tumour size, tumour site, and immunosuppression. RR=relative risk. *Surgery–imiquinod. 
†Imiquinod relative to surgery. ‡From likelihood ratio test. §Primary analysis of interest is head and neck at 6 months. 
Table 4: Cosmetic appearance of lesion (excellent or good) at 6 months and 3 years as rated by two independent dermatologists
Articles
102 www.thelancet.com/oncology   Vol 15   January 2014
withdrew because of adverse events (ﬁ ve [42%] of these 
events were treatment related, three [25%] were part of 
treatment failure, and two [17%] were non-related 
events leading to death as reason for withdrawal). Four 
(2%) of 229 participants withdrew because of adverse 
events in the surgery group (all non-related events, 
three [75%] of which led to death). No deaths or serious 
adverse events were regarded as related to treatment. 
15 (6%) of 249 patients were assessed to have received 
insuﬃ  cient imiquimod from compliance diaries, sachet 
returns, and dose reductions (appendix).
The appendix shows results of the cost-eﬀ ectiveness 
analysis.
Discussion
Our ﬁ ndings show that imiquimod is inferior to surgery 
for treatment of basal-cell carcinoma because it failed to 
reach our predeﬁ ned non-inferiority margin after 3 years 
of follow-up. Signiﬁ cantly more tumours recurred in 
patients in the imiquimod group than in those in the 
surgical group in the time leading up to the ﬁ rst year. We 
did not record any evidence of patient-rated cosmetic 
gain for imiquimod that could be traded oﬀ  against the 
lower eﬃ  cacy of imiquimod. However, dermatologist-
rated cosmetic outcome was better overall for topical 
imiquimod. Slightly more participants in the imiquimod 
group reported pain on treatment than in the surgical 
group, although direct comparisons were diﬃ  cult 
because treatment times diﬀ ered substantially and pain 
relief was often given routinely after surgery. More 
patients had adverse events when treated with the cream 
than those in the surgery group; however, more patients 
who underwent surgery had adverse events in the follow-
up period. The total costs between treatment methods 
were not signiﬁ cantly diﬀ erent.
The proportion of patients who had successful 
treatment with topical imiquimod for superﬁ cial basal-
cell carcinoma at 1 year in our study is similar to those 
(87–88%) reported in our Cochrane review,7 and in a 
subsequent review that included non-randomised trials, 
which reported a pooled estimate of 86·2% (95% CI 
82–90) for the proportion of patients with a complete 
response.9 83·4% of patients with superﬁ cial basal-cell 
carcinoma treated with topical imiquimod used ﬁ ve 
times per week responded to treatment as assessed after 
12 months in a recent study from the Netherlands, 
compared with 72·8% of patients treated with 
photodynamic therapy and 80·1% of patients treated 
with ﬂ uorouracil cream.19 Findings from another study 
suggested that thicker lesions (>0·4 mm thickness) 
might be much more likely to recur than thin lesions.20
In our study, where patients were treated with imiquimod 
daily, more patients with nodular basal-cell carcinoma 
were successfully treated at 1 year compared with another 
study that used imiquimod three times a week for either 
8 weeks or 12 weeks and reported a successful treatment of 
64% of patients,21 and with a review that suggested a 76% 
treatment response for nodular tumours.7 An open-label 
study of imiquimod (used once daily for 6 weeks) for 
superﬁ cial basal-cell carcinoma reported a 10% cumulative 
recurrence at 3 years.22 Another open label study23 of 
imiquimod (ﬁ ve times a week for 6 weeks) for superﬁ cial 
basal-cell carcinoma showed a cumulative recurrence of 
8·6% at 3 years.
We did not rebiopsy patients with basal-cell carcinoma 
given topical imiquimod to conﬁ rm tumour clearance 
because this population would not be routinely biopsied 
if the lesion were regarded as clinically clear. Additionally, 
further biopsy might induce an inﬂ ammatory response 
that could enhance treatment response. Furthermore, a 
biopsy scar would have aﬀ ected the cosmetic result for 
Participants Events
Imiquimod Surgery Imiquimod Surgery
Adverse event in ﬁ rst 6 months after start of treatment
Superﬁ cial 120/128 (94%) 105/114 (92%) 754 521
Nodular 120/126 (95%) 97/115 (84%) 713 380
All 240/254 (94%) 202/229 (88%) 1467 901
ADR in ﬁ rst 6 months after start of treatment
Superﬁ cial 103/128 (80%) 79/114 (69%) 376 234
Nodular 107/126 (85%) 69/115 (60%) 449 187
All 210/254 (83%) 148/229 (65%) 825 421
Adverse event during trial (up to 3 years)
Superﬁ cial 121/128 (95%) 107/114 (94%) 755 525
Nodular 121/126 (96%) 101/115 (88%) 714 388
All 242/254 (95%) 208/229 (91%) 1469 913
ADR during trial (up to 3 years)
Superﬁ cial 104/128 (81%) 79/114 (69%) 377/755 (50%) 234/525 (45%)
Nodular 108/126 (86%) 70/115 (61%) 450/714 (63%) 188/388 (48%)
All 212/254 (83%) 149/229 (65%) 827/1469 (56%) 422/913 (46%)
Serious adverse event*
Superﬁ cial 52/128 (41%) 60/114 (53%) 124/755 (16%) 115/525 (22%)
Nodular 47/126 (37%) 37/115 (32%) 83/714 (12%) 85/388 (22%)
All 99/254 (39%) 97/229 (42%) 207/1469 (14%) 200/913 (22%)
Adverse events of moderate or severe intensity
Superﬁ cial 24/128 (19%) 23/114 (20%) 158/755 (21%) 116/525 (22%)
Nodular 26/126 (21%) 22/115 (19%) 138/714 (19%) 108/388 (28%)
All 50/254 (20%) 45/229 (20%) 296/1469 (20%) 224/913 (25%)
Adverse events for which drugs were taken
Superﬁ cial 88/128 (69%) 76/114 (67%) 249/755 (33%) 216/525 (41%)
Nodular 71/126 (56%) 63/115 (55%) 177/714 (25%) 146/388 (38%)
All 159/254 (63%) 139/229 (61%) 426/1469 (29%) 362/913 (40%)
Adverse events resulting in change in imiquimod dose 
Superﬁ cial 15/128 (12%) ·· 31 ··
Nodular 23/126 (18%) ·· 64 ··
All 38/254 (15%) ·· 95 ··
Data are n (%) or n. Proportions for some events have not been provided if we deemed them unuseful (eg, number of 
adverse events in the ﬁ rst 6 months compared with those at 3 years, when criteria changed for collection of such 
events after 1 year). After 1 year from treatment start, we recorded only serious or possible treatment-related events. 
Five adverse events resulting in withdrawal were treatment related (all in patients in the imiquimod group). Four (2%) 
in the imiquimod group had wound infections and 12 (5%) in the surgery group. *No serious adverse events were 
treatment related. ADR=possibly treatment related adverse event.
Table 6: Number of participants who had adverse events and number of adverse events (safety dataset)
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imiquimod, which was an important outcome to measure 
in this study.
Few studies have compared the cost-eﬀ ectiveness of 
surgical treatment versus topical imiquimod for 
superﬁ cial basal-cell carcinoma. One study24 estimated 
the mean cost per patient given imiquimod 5% cream to 
be lower than that of a patient assigned surgery for a 
superﬁ cial basal-cell carcinoma (621 vs 676 euros), but 
costs associated with treatment of initial treatment 
failures or recurrences were not addressed. Another 
study25 compared the cost of imiquimod with surgery 
and reported imiquimod to be more cost eﬀ ective in the 
short term but more expensive in the long term. One 
study26 compared the cost-eﬀ ectiveness of imiquimod 
with that of a range of other treatments and showed the 
cost of imiquimod to be higher. Future studies might 
compare other treatments used for low-risk basal-cell 
carcinomas, such as electrodesiccation and curettage, 
with topical imiquimod or photodynamic therapy.
To our knowledge this study is the ﬁ rst large, 
independent, pragmatic study comparing imiquimod 
with surgery in a wide range of patients who might 
typically be considered for such treatment in primary 
care (panel). Selection bias was unlikely due to strong 
concealment of the allocation sequence, and the 
modiﬁ ed intention-to-treat analysis shows similar 
results to our per-protocol analysis. There were few 
missing data for the risk factors we adjusted for, so this 
issue had little eﬀ ect on the number of participants on 
which our regression models were based. Study 
limitations include the fact that we used imiquimod 
7 days a week, rather than the presently licensed 5 days a 
week. Increased participant support in the use of 
imiquimod and dealing with side-eﬀ ects might have 
improved results in the imiquimod group. Additionally, 
some of the surgeons were trained in advanced surgery 
Panel: Research in context
Systematic review
We did a Cochrane systematic review of interventions for 
basal-cell carcinoma when planning our study in 2002, 
which we then updated in 2007.7 In the Cochrane review we 
searched six databases and contacted companies and 
identiﬁ ed 27 randomised controlled trials of mainly poor 
quality as judged by method of randomisation, allocation 
concealment, blinding, and whether an intention-to-treat 
analysis and unit of analysis issues were considered. The 
largest study included 347 patients. Nine short-term 
studies combined using a random-eﬀ ects model suggested 
a success rate of 87% for imiquimod in the treatment of 
superﬁ cial basal-cell carcinoma with a once-daily regimen 
for 6 weeks, and a 76% treatment response with treatment 
of nodular basal-cell carcinoma for 12 weeks, when 
measured histologically. We then searched PubMed and 
CENTRAL from January, 2006, to June, 2013, with the same 
terms as used in our Cochrane review, to identify new 
relevant studies of interventions for basal-cell carcinoma. 
None of the newly identiﬁ ed studies directly compared 
topical imiquimod with excisional surgery.
Interpretation
To our knowledge this study is the ﬁ rst large, independent, 
pragmatic study comparing imiquimod with surgery in 
patients who might typically be considered for such treatment 
in primary care. Our ﬁ ndings show that topical imiquimod is 
inferior to surgery  with no clear cosmetic or cost beneﬁ ts. 
Success rates for excisional surgery  were high. The study 
provides a useful estimate of response rates for topical 
imiquimod in clinical practice for both low-risk superﬁ cial and 
nodular basal-cell carcinoma at 3 years. Topical imiquimod 
might still be a useful treatment option for people with low-risk 
basal-cell carcinomas who have more than one superﬁ cial 
basal-cell carcinoma, those treated in primary care where 
success rates for excisional surgery can be considerably lower 
than in secondary care, and for those who prefer to use a cream 
at home, especially since recurrences are usually easy to identify 
and deal with surgically. Other treatments for low-risk and 
multiple basal-cell carcinomas include photodynamic therapy, 
electrodesiccation and curettage, topical ﬂ uorouracil, and 
cryotherapy. However, none of these treatments have been 
assessed long term, except for photodynamic therapy,27 which 
has shown similar long-term response rates to those reported 
for imiquimod in this study.
Imiquimod 
(n=249)
Surgery 
(n=229)
Patients who had higher frequency mild or moderate adverse events*
Itching at tumour site 211 (85%) 129 (56%)
Weeping at tumour site 160 (64%) 81 (35%)
New basal-cell carcinoma 64 (26%) 55 (24%)
Erythema or redness at tumour site 56 (22%) 9 (4%)
Cold or ﬂ u-type symptoms or feeling of unwell 53 (21%) 21 (9%)
Headache 39 (16%) 38 (17%)
Scab on tumour site 33 (13%) 1 (<1%)
Small spots or pimples close to trial tumour 30 (12%) 5 (2%)
Soreness of tumour site 24 (10%) 16 (7%)
Bleeding at tumour site 21 (8%) 8 (3%)
Pain at tumour site 12 (5%) 17 (7%)
Swelling at tumour site 10 (4%) 19 (8%)
Patients who had higher frequency severe, life-threatening, 
or disabling events†
Cold or ﬂ u-type symptoms 7 (3%) 0 
Inﬂ ammatory reaction to treatment 4 (2%) 0 
Heart attack or heart failure 3 (1%) 4 (2%)
Pneumonia 1 (<1%) 4 (2%)
Data are n (%), unless otherwise indicated. *>5% in either group. †>1% in either 
group 
Table 7: Number of participants who had higher frequency mild or 
moderate or severe, life-threatening, or disabling adverse events of all 
types (safety dataset)
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and were therefore not typical primary-care or secondary-
care professionals, which means that the surgical results 
in this study might have been better than what would be 
observed in general practice. Comparisons of pain on 
treatment were diﬃ  cult because the time for which 
patients used imiquimod was much longer than the 
1 day in which patients underwent for surgery. Absence 
of a masked clinical assessment at 3 years might have 
favoured surgery because it was done by those who 
traditionally undertake surgery. We also lost some 
precision in our estimates of treatment eﬀ ects by 
revising our sample size from 740 to 500 for pragmatic 
reasons. 
In terms of external validity, the study could have 
favoured slightly younger people with basal-cell 
carcinoma who were more mobile than some of the 
older and more frail patients who declined to participate; 
furthermore, individuals entering the study were 
motivated about the prospect of use of topical 
imiquimod, which was not licensed for basal-cell 
carcinoma at the start of the study.
Although our study showed imiquimod to be inferior 
to surgery according to our predeﬁ ned non-inferiority 
margin, others might consider the overall success rate at 
3 years still clinically useful, especially because low-risk 
recurrences of basal-cell carcinoma can be treated. In 
other words, some policy makers might consider use of 
topical imiquimod as part of a sequential treatment 
approach that treats most people with low-risk lesions 
successfully at home and those who fail with surgery. 
Use of imiquimod cream for low-risk basal-cell 
carcinoma might be a matter of patient choice guided by 
convenience and acceptability of the intervention, 
although it should be pointed out that surgery is more 
eﬀ ective and leads to similar patient-adjudicated 
cosmetic outcomes as does imiquimod cream. The 
diﬀ erence between surgery and imiquimod cream might 
be less in primary care than reported in this study 
because family doctors perform surgery less successfully 
(complete excision in 32–78% of patients) than 
dermatologists (72–92%).28–31 A stronger case can be 
made for treatment of superﬁ cial basal-cell carcinoma at 
low-risk sites to be managed in primary care with 
imiquimod than for low-risk nodular tumours. Such 
patients would need to be followed up long-term in view 
of the lower success of imiquimod compared with 
surgery. Excisional surgery remains the best treatment 
for low-risk basal-cell carcinoma, but other factors, such 
as patient choice, size and site of the lesion, and whether 
the patient has more than one lesion, might allow 
alternative treatments such as imiquimod cream, 
ﬂ uorouracil cream, and photo dynamic therapy to be 
considered.19,27
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